



## Specialty Tier Reform Update – Week of September 21, 2015

By Mark Hobracczk, JD, MPA

### STATES

#### District of Columbia

##### ***Public hearing scheduled on bill to limit specialty drug copayments***

The Committee on Business, Consumer, and Regulatory Affairs has scheduled an October 28<sup>th</sup> public hearing on B21-32, the *Specialty Drug Copayment Limitation Act of 2015*.

Introduced in January, the bill would limit the amount of copayment or coinsurance that individuals must pay for a prescribed specialty drug to \$150 per month for up to a 30-day supply (see Specialty Tier Reform Update for Week of January 19<sup>th</sup>).

Individuals and representatives of organizations who wish to testify at the public hearing should contact Faye Caldwell of the Committee on Business, Consumer, and Regulatory Affairs by October 26<sup>th</sup> at [fcaldwell@dccouncil.us](mailto:fcaldwell@dccouncil.us).

#### Massachusetts

##### ***Committee to hold hearing on impact of specialty drug costs***

The Joint Committee on Public Health has scheduled a September 29<sup>th</sup> public hearing on H.B. 2072, which would require that the Health Policy Commission annually conduct an analysis on the impact of specialty drug costs on Massachusetts' cost containment benchmark. The bill would require a report to be issued to the legislature on July 1<sup>st</sup> of every year as well as annual cost containment hearings.

Witnesses at the public hearing must include at least three pharmaceutical companies, one of which does business in specialty pharmacy.